Valid Analysis of Brain-Specific Progression-Free Survival
Author:
Affiliation:
1. Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, Massachusetts
2. Department of Gastrointestinal Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston
Publisher
American Medical Association (AMA)
Link
https://jamanetwork.com/journals/jamaoncology/articlepdf/2820086/jamaoncology_armbruster_2024_le_240015_1723659894.39694.pdf
Reference5 articles.
1. Whole-brain radiotherapy alone vs preceded by bevacizumab, etoposide, and cisplatin for untreated brain metastases from breast cancer: a randomized clinical trial.;Chen;JAMA Oncol,2024
2. Interpretability of cancer clinical trial results using restricted mean survival time as an alternative to the hazard ratio.;Pak;JAMA Oncol,2017
3. Moving beyond the hazard ratio in quantifying the between-group difference in survival analysis.;Uno;J Clin Oncol,2014
4. Efficiency of two sample tests via the restricted mean survival time for analyzing event time observations.;Tian;Biometrics,2018
5. Progressing bevacizumab-induced diffusion restriction is associated with coagulative necrosis surrounded by viable tumor and decreased overall survival in patients with recurrent glioblastoma.;Nguyen;AJNR Am J Neuroradiol,2016
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3